Cargando…

Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy

SIMPLE SUMMARY: Evaluation of the prognostic significance of serial measurements of serum concentrations of Krebs von den Lungen-6 (KL-6) showed that an annual increment in KL-6 exceeding a threshold amount was an independent risk factor for progressive disease and poor prognosis. No literature data...

Descripción completa

Detalles Bibliográficos
Autores principales:	d’Alessandro, Miriana, Bergantini, Laura, Cameli, Paolo, Pieroni, Maria, Refini, Rosa Metella, Sestini, Piersante, Bargagli, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914581/ https://www.ncbi.nlm.nih.gov/pubmed/33572070 http://dx.doi.org/10.3390/cancers13040689

Ejemplares similares

Systematic Review and Metanalysis of Oncomarkers in IPF Patients and Serial Changes of Oncomarkers in a Prospective Italian Real-Life Case Series
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Serial KL-6 measurements in COVID-19 patients
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Adaptive immune system in pulmonary sarcoidosis—Comparison of peripheral and alveolar biomarkers
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6
por: Bergantini, Laura, et al.
Publicado: (2019)

Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review
por: Cameli, Paolo, et al.
Publicado: (2020)

KL-6 in ANCA-Associated Vasculitis Patients with and without ILD: A Machine Learning Approach
por: Conticini, Edoardo, et al.
Publicado: (2022)

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
por: Cameli, Paolo, et al.
Publicado: (2020)

The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study
por: Cameli, Paolo, et al.
Publicado: (2022)

Specific Serum Markers of IPF: What Is the Significance of KL-6, SP-A, and SP-D?
por: Chiba, Hirofumi, et al.
Publicado: (2015)

Krebs von den Lungen-6 (KL-6) in cerebrospinal fluid from neurosarcoidosis patients
por: Bocci, Silvia, et al.
Publicado: (2023)

Extracellular Vesicle Surface Signatures in IPF Patients: A Multiplex Bead-Based Flow Cytometry Approach
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

Hypercalciuria in Sarcoidosis: A Specific Biomarker With Clinical Utility
por: Cameli, Paolo, et al.
Publicado: (2020)

BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures
por: Vantaggiato, Lorenza, et al.
Publicado: (2023)

The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis
por: Refini, Rosa Metella, et al.
Publicado: (2020)

Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena
por: Vietri, Lucia, et al.
Publicado: (2020)

Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis
por: Bargagli, Elena, et al.
Publicado: (2020)

Correction to: Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis
por: Bennett, David, et al.
Publicado: (2020)

Prognostic Significance of Obstructive Sleep Apnea in a Population of Subjects with Interstitial Lung Diseases
por: Valecchi, Debora, et al.
Publicado: (2023)

Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis
por: Bennett, David, et al.
Publicado: (2020)

NK and T Cell Immunological Signatures in Hospitalized Patients with COVID-19
por: Bergantini, Laura, et al.
Publicado: (2021)

KL-6 in ARDS and COVID-19 Patients
por: Piazza, Ornella, et al.
Publicado: (2022)

Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
por: Bergantini, Laura, et al.
Publicado: (2021)

Alveolar Nitric Oxide as a Biomarker of COVID-19 Lung Sequelae: A Pivotal Study
por: Cameli, Paolo, et al.
Publicado: (2021)

Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review
por: Bergantini, Laura, et al.
Publicado: (2022)

KL-6 levels in COVID-19
por: Scarpati, G, et al.
Publicado: (2020)

Seasonal variation of serum KL-6 concentrations is greater in patients with hypersensitivity pneumonitis
por: Ohnishi, Hiroshi, et al.
Publicado: (2014)

Exploring the Interaction between Fractional Exhaled Nitric Oxide and Biologic Treatment in Severe Asthma: A Systematic Review
por: Pianigiani, Tommaso, et al.
Publicado: (2023)

Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience
por: Levra, Stefano, et al.
Publicado: (2022)

Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases
por: Bergantini, Laura, et al.
Publicado: (2020)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
por: Torrisi, Sebastiano Emanuele, et al.
Publicado: (2019)

Oxygen Therapy during Exercise in Patients with Interstitial Lung Diseases
por: Viani, Magda, et al.
Publicado: (2022)

Clinical Impact of the KL-6 Concentration of Pancreatic Juice for Diagnosing Pancreatic Masses
por: Matsumoto, Kazuya, et al.
Publicado: (2015)

Effect of Ambulatory Oxygen on the Respiratory Pattern during the 6 Min Walking Test in Patients with Interstitial Lung Diseases
por: Ventura, Vittoria, et al.
Publicado: (2023)

Clinical phenotyping in sarcoidosis management
por: Rana, Giuseppe Domenico, et al.
Publicado: (2021)

Keynote Lectures (KL)
Publicado: (2017)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
por: Finnerty, James Patrick, et al.
Publicado: (2021)

Development of the ATAQ-IPF: a tool to assess quality of life in IPF
por: Swigris, Jeffrey J, et al.
Publicado: (2010)

Cytomegalovirus Infection Is Associated with Development of Chronic Lung Allograft Dysfunction
por: Bennett, David, et al.
Publicado: (2022)

Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
por: Vu, Tuong N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_16n6l0telbbgs369d9qo4ekkb5